يعرض 1 - 10 نتائج من 10 نتيجة بحث عن '"Pulmons -- Càncer -- Immunoteràpia"', وقت الاستعلام: 1.40s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Zhou C Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Affiliated Shanghai Pulmonary Hospital, Shanghai, China. Srivastava MK Oncology Biomarker Development, Genentech Inc, South San Francisco, California, USA. Xu H F. Hoffman-La Roche Ltd, Mississauga, Ontario, Canada. Felip E Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Wakelee H Stanford University School of Medicine, Stanford Cancer Institute, Stanford, California, USA. Altorki N Department of Cardiothoracic Surgery, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, New York, USA, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal for ImmunoTherapy of Cancer;11(10); http://dx.doi.org/10.1136/jitc-2023-007047Test; Zhou C, Srivastava MK, Xu H, Felip E, Wakelee H, Altorki N, et al. Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial. J Immunother Cancer. 2023 Oct;11(10):e007047.; https://hdl.handle.net/11351/10606Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Nadal E Department of Medical Oncology, Catalan Institute of Oncology, IDIBELL, L’Hospitalet, Barcelona, Spain. Saleh M University of Alabama, Birmingham, AL, USA. Aix SP Hospital 12 de Octubre – Oncology, Madrid, Spain. Ochoa-de-Olza M Vall d’Hebron Hospital Universitari, Barcelona, Spain. Patel SP University of California, San Diego, CA, USA. Antonia S H. Lee Moftt Cancer Center and Research Institute, Tampa, FL, USA, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: BMC Cancer;23; https://doi.org/10.1186/s12885-023-11153-1Test; Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, et al. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer. 2023 Jul 28;23:708.; https://hdl.handle.net/11351/10137Test

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Arriola E Medical Oncology Department, Hospital Universitari del Mar-CIBERONC, Barcelona, Spain. González-Cao M Medical Oncology Department (IOR), Hospital Dexeus, Barcelona, Spain. Domine M Medical Oncology Department, Fundación Jiménez Díaz, Madrid, Spain. De Castro J Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain. Cobo M Inter-Center Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. Bernabé R Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain. Navarro A Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Oncology and Therapy;10; https://doi.org/10.1007/s40487-021-00182-0Test; Arriola E, González-Cao M, Domine M, De Castro J, Cobo M, Bernabé R, et al. Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Oncol Ther. 2022 Jun;10:167–84.; https://hdl.handle.net/11351/9684Test; 000742566400001

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Peters S Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland. Dziadziuszko R Medical University of Gdańsk, Gdańsk, Poland. Morabito A Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Naples, Italy. Felip E Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Gadgeel SM Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI, USA. Cheema P William Osler Health System, University of Toronto, Brampton, Ontario, Canada, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Nature Medicine;28; https://doi.org/10.1038/s41591-022-01933-wTest; Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel SM, Cheema P, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nat Med. 2022 Sep;28:1831–9.; https://hdl.handle.net/11351/9339Test; 000842907100002

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Domingues I Medical Oncology Department, Portuguese Institute of Oncology of Coimbra, Coimbra, Portugal. Cedres S, Callejo A, Martinez-Marti A, Felip E Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vivancos A Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Pulmonology;26(1); https://doi.org/10.1016/j.pulmoe.2019.05.002Test; Domingues I, Cedres S, Callejo A, Vivancos A, Martinez-Marti A, Felip E. Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient. Pulmonology. 2019 Jan;26(1):49–50.; https://hdl.handle.net/11351/6479Test; 000505089100008

  6. 6
    تقرير

    المساهمون: Departament de Salut

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Programa d'Harmonització Farmacoterapèutica. Tractament del CPNM metastàtic en primera i segona línia amb immunoteràpia: informe d'avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.; https://hdl.handle.net/11351/6198Test

  7. 7

    المساهمون: Institut Català de la Salut, [Peters S] Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland. [Dziadziuszko R] Medical University of Gdańsk, Gdańsk, Poland. [Morabito A] Istituto Nazionale Tumori ‘Fondazione G Pascale’, IRCCS, Naples, Italy. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Gadgeel SM] Henry Ford Cancer Institute/Henry Ford Health System, Detroit, MI, USA. [Cheema P] William Osler Health System, University of Toronto, Brampton, Ontario, Canada, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    مصطلحات موضوعية: Lung Neoplasms, phase 3 trial, Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Marcadors tumorals, terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], blood-based tumor, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS], Atezolizumab versus chemotherapy, NSCLC, blood-based tumor, mutational burden, phase 3 trial, General Medicine, Pulmons - Càncer - Immunoteràpia, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], NSCLC, Antibodies, Monoclonal, Humanized, Other subheadings::Other subheadings::/drug therapy [Other subheadings], General Biochemistry, Genetics and Molecular Biology, Atezolizumab versus chemotherapy, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Immunotherapy, Biological Factors::Biomarkers::Biomarkers, Tumor [CHEMICALS AND DRUGS], mutational burden

    وصف الملف: application/pdf

  8. 8

    المساهمون: Universidad de Sevilla. Departamento de Medicina, Institut Català de la Salut, [Arriola E] Medical Oncology Department, Hospital Universitari del Mar-CIBERONC, Barcelona, Spain. [González-Cao M] Medical Oncology Department (IOR), Hospital Dexeus, Barcelona, Spain. [Domine M] Medical Oncology Department, Fundación Jiménez Díaz, Madrid, Spain. [De Castro J] Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain. [Cobo M] Inter-Center Medical Oncology Clinical Management Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain. [Bernabé R] Medical Oncology Department, Hospital Virgen del Rocío, Sevilla, Spain. [Navarro A] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

  9. 9
  10. 10

    المساهمون: Institut Català de la Salut, [Domingues I] Medical Oncology Department, Portuguese Institute of Oncology of Coimbra, Coimbra, Portugal. [Cedres S, Callejo A, Martinez-Marti A, Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Vivancos A] Cancer Genomics Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf